FrancophonIA/ELRC3.0 huggingface dataset:
English: In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.
Danish: Som følge af manglen på tilgængelige data bør behandling af hvalpe, der er under 8 uger gamle, og/eller hunde med en kropsvægt på mindre end 1,3 kg baseres på en benefit-risk-vurdering af den ansvarlige dyrlæge.
English: Use appropriate combination of available strengths to achieve the recommended dose of 2-4 mg/kg.
Danish: Brug en passende kombination af de styrker, der er til rådighed, for at opnå den anbefalede dosis på 2-4 mg/kg.
English: The veterinary medicinal product should be administered at a dose of 2-4 mg/kg bodyweight in accordance with the following table:
Danish: Veterinærlægemidlet skal administreres i doser af 2-4 mg/kg legemsvægt i henhold til følgende tabel:
English: Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.
Danish: Sarolaner binder sig stærkt til plasmaproteiner og kan konkurrere med andre stærkt bundne stoffer som f.eks. non-steroide anti-inflammatoriske lægemidler (NSAID'er) og cumarinderivatet warfarin.
English: For the treatment of ear mite infestations (Otodectes cynotis) a single dose should be administered.
Danish: Til behandling af øremide infestationer (Otodectes cynotis) bør der administreres en enkelt dosis.
English: The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in animals intended for breeding.
Danish: Lægemidlets sikkerhed under drægtighed og laktation er ikke fastlagt; heller ikke for dyr, der er beregnet til avl.
English: For the treatment of demodicosis (Demodex canis).
Danish: Til behandling af Demodex (hårsækkemideangreb) (Demodex canis).
English: The depletion from tissues was consistent with the plasma half-life.
Danish: Udtømning af vævet svarede til halveringstid i plasma.
English: The veterinary medicinal product kills newly emerged fleas on the dog before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access.
Danish: Veterinærlægemidlet dræber nye lopper på hunden, før de kan lægge æg, og hindrer således spredning af lopperne til de områder, hvor hunden færdes.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON
Danish: OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE ÆSKE
English: Sarolaner was dose proportional in Beagle dogs when dosed from the intended use dose of 2-4 mg/kg, to 20 mg/kg.
Danish: Sarolaner var dosisproportional hos beaglehunde, når dosis var fra den beregnede dosis på 2-4 mg/kg og op til 20 mg/kg.
English: In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum exposure dose and convulsions at 5 times the maximum exposure dose.
Danish: I den gruppe, der fik en overdosis, blev der observeret forbigående og selvbegrænsende neurologiske tegn hos nogle af dyrene: svag tremor ved 3 gange den maksimale eksponeringsdosis og konvulsioner ved 5 gange den maksimale eksponeringsdosis.
English: For the treatment of sarcoptic mange (Sarcoptes scabiei).
Danish: Til behandling af skab (Sarcoptes scabiei).
English: Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
Danish: Lopper og flåter skal sætte sig på værten og begynde at æde for at blive eksponeret for det aktive stof.
English: During clinical field trials, no interactions between MiPet Easecto chewable tablets for dogs and routinely used veterinary medicinal products were observed.
Danish: I forbindelse med kliniske feltstudier blev der ikke observeret interaktion mellem MiPet Easectotyggetabletter til hunde og rutinemæssigt anvendte veterinærlægemidler.
English: In a margin of safety study, the veterinary medicinal product was administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum exposure dose of 4 mg/kg at 28 day intervals for 10 doses.
Danish: I forbindelse med en undersøgelse af sikkerhedsmarginen for produktet blev veterinærlægemidlet administreret oralt til 8 uger gamle beaglehvalpe i doser på 0, 1, 3 og 5 gange den maksimale ekponeringsdosis på 4 mg/kg i 28 dages intervaller med 10 doser.
English: The number embossed on one side refers to the strength (mg) of the tablet: “5”, “10”, ”20”, “40”, “80” or “120”.
Danish: Det prægede tal på den ene side henviser til tablettens styrke (mg): ”5”, ”10”, ”20”, ”40”, ”80” eller ”120”.
English: Mild and transient gastrointestinal signs such as vomiting and diarrhoea, transient neurological disorders such as tremor, ataxia or convulsion and systemic disorders such as lethargy, anorexia/inappetence may occur in very rare cases.
Danish: Lette, forbigående gastrointestinale tegn (f.eks. opkastning og diarré), forbigående neurologiske reaktioner (f.eks. tremor, nedsat ataxi og kramper) og systemiske lidelser som letargi, anoreksi eller appetitløshed kan forekomme i meget sjældne tilfælde.
English: For the treatment of ear mite infestations (Otodectes cynotis).
Danish: Til behandling af øremide infestationer (Otodectes cynotis).
English: For optimal control of tick and fleas infestations, the veterinary medicinal product should be administered at monthly intervals and continue throughout the flea and/or tick season based on local epidemiological situations.
Danish: For at opnå optimal kontrol over flåt- og loppeangrebet skal veterinærlægemidlet administreres månedligt, og behandlingen bør fortsætte gennem hele loppe- og/eller flåtsæsonen ud fra lokale epidemiologiske forhold.
English: One
Danish: En
English: The veterinary medicinal product has immediate and persistent tick killing activity for at least 5 weeks.
Danish: Veterinærlægemidlet virker øjeblikkeligt og dræber flåter i mindst 5 uger.
English: For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus).
Danish: Til behandling af flåtangreb (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus og Rhipicephalus sanguineus).
English: PSUR submissions for MiPet Easecto shall be synchronised and submitted at the same frequency as for Simparica.
Danish: Den periodiske, opdaterede sikkerhedsindberetninger (PSUR) cyklus skal synkroniseres og indsendes i samme tidsplan som for Simparica.
English: For the treatment of demodicosis (caused by Demodex canis) the administration of a single dose once monthly for three consecutive months is efficacious and leads to a marked improvement of clinical signs.
Danish: Ved behandling af Demodex (hårsækkemideangreb) (forårsaget af Demodex canis) er en enkelt dosis en gang månedligt 3 måneder i træk effektiv og fører til udpræget forbedring af de kliniske tegn.
English: PACKAGE LEAFLET: MiPet Easecto chewable tablets for dogs
Danish: INDLÆGSSEDDEL MiPet Easecto tyggetabletter til hunde
English: Disruption of these receptors by sarolaner prevents the uptake of chloride ions by GABA and glutamate gated ion channels, thus resulting in increased nerve stimulation and death of the target parasite.
Danish: Når disse receptorer ødelægges af sarolaner, hindres optagelsen af kloridioner af GABA og de glutamat-styrede ionkanaler, hvilket resulterer i øget nervestimulation og døden for den parasit, der er målet for behandlingen.
English: In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate.
Danish: Laboratoriebaserede undersøgelser af sikkerheden påviste ingen interaktion, når sarolaner blev administreret samtidigt med milbemycinoxim, moxidectin og pyrantelpamoat.
English: MiPet Easecto chewable tablets sarolaner (mg)
Danish: MiPet Easecto tyggetabletter sarolaner (mg)
English: For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) a single dose should be administered at monthly intervals for two consecutive months.
Danish: Ved behandling af skab (forårsaget af Sarcoptes scabiei var. canis) bør der administreres en enkelt dosis månedligt i 2 måneder i træk.
English: Hypromellose acetate succinate, medium grade Lactose monohydrate
Danish: Hypromellose acetate succinate, medium Laktosemonohydrat
English: Each tablet contains: MiPet Easecto chewable tablets sarolaner (mg)
Danish: Hver tyggetablet indeholder: MiPet Easecto tyggetabletter sarolaner (mg)
English: For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis).
Danish: Til behandling af loppeangreb (Ctenocephalides felis og Ctenocephalides canis).
English: Aluminium foil/foil blister package.
Danish: Aluminiumsfolie/blisterpakning i aluminiumsfolie.
English: No adverse effects were observed at the maximum exposure dose of 4 mg/kg.
Danish: Ved den maksimale eksponeringsdosis 4 mg/kg forekom der ingen bivirkninger.
English: For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after product administration.
Danish: For lopperne indtrådte virkningen inden for 8 timer, efter loppen havde bidt sig fast, i løbet af 28 dage efter administration af produktet.
English: Number of tablets to be administered
Danish: Administration af antal tabletter
English: For each strength, the chewable tablets are available in a carton with 1 blister of 3 tablets.
Danish: Tyggetabletterne fås i de forskellige styrker i pakning af følgende størrelse: æske med en blisterpakning med 3 tabletter.
English: For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration.
Danish: For flåterne (I. ricinus) indtrådte virkningen inden for 12 timer, efter flåten havde bidt sig fast, inden for 28 dage efter administration af produktet.
English: Sarolaner is active against adult fleas (Ctenocephalides felis and Ctenocephalides canis) as well as several tick species such as Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, Rhipicephalus sanguineus and the mites Demodex canis, Otodectes cynotis and Sarcoptes scabiei.
Danish: Sarolaner virker mod voksne lopper (Ctenocephalides felis og Ctenocephalides canis) samt flere forskellige flåtarter Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus og Rhipicephalus sanguineus og midearterne Demodex canis, Otodectes cynotis og Sarcoptes scabiei.
English: Sodium starch glycolate Silica, colloidal anhydrous Magnesium stearate
Danish: Natriumstivelsesglykolat Silica, kolloid vandfri Magnesiumstearat
English: Mottled brown coloured, square shaped chewable tablets with rounded edges.
Danish: Brunmarmorerede, firkantede tyggetabletter med afrundede hjørner.
English: MiPet Easecto tablets are chewable and palatable and readily consumed by dogs when offered by the owner.
Danish: Hunde fortærer dem beredvilligt, når de tilbydes af ejeren.
English: The primary route of elimination is biliary excretion of parent molecule, with elimination through the faeces.
Danish: Lægemidlet udskilles primært via galden sammen med hovedmolekylet og føres ud med afføringen.
English: The blister pack should be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children.
Danish: Blisterpakningen skal straks efter brug lægges tilbage i æsken, som opbevares utilgængeligt for børn.
English: for dogs 1.3-2.5 kg for dogs >2.5-5 kg for dogs >5-10 kg for dogs >10-20 kg for dogs >20-40 kg for dogs >40-60 kg
Danish: til hunde 1,3-2,5 kg til hunde > 2,5-5 kg til hunde > 5-10 kg til hunde > 10-20 kg til hunde > 20-40 kg til hunde > 40-60 kg
English: Parasites need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious parasite-borne diseases cannot be excluded.
Danish: Parasitterne skal begynde at æde på værten for at blive eksponeret for sarolaner.
English: AUTHORISATION
Danish: Behandling
English: The prandial state of the dog does not significantly affect the extent of its absorption.
Danish: Om hunden indtog lægemidlet med eller uden mad havde ikke nogen signifikant indvirkning på absorberingen.
English: MiPet Easecto 5 mg chewable tablets for dogs 1.3-2.5 kg MiPet Easecto 10 mg chewable tablets for dogs >2.5-5 kg MiPet Easecto 20 mg chewable tablets for dogs >5-10 kg MiPet Easecto 40 mg chewable tablets for dogs >10-20 kg MiPet Easecto 80 mg chewable tablets for dogs >20-40 kg MiPet Easecto 120 mg chewable tablets for dogs >40-60 kg sarolaner
Danish: MiPet Easecto 5 mg tyggetabletter til hunde på 1,3-2,5 kg MiPet Easecto 10 mg tyggetabletter til hunde på > 2,5-5 kg MiPet Easecto 20 mg tyggetabletter til hunde på > 5-10 kg MiPet Easecto 40 mg tyggetabletter til hunde på > 10-20 kg MiPet Easecto 80 mg tyggetabletter til hunde på > 20-40 kg MiPet Easecto 120 mg tyggetabletter til hunde på > 40-60 kg sarolaner
English: MiPet Easecto 5 mg chewable tablets for dogs 1.3-2.5 kg MiPet Easecto 10 mg chewable tablets for dogs >2.5-5 kg MiPet Easecto 20 mg chewable tablets for dogs >5-10 kg MiPet Easecto 40 mg chewable tablets for dogs >10-20 kg MiPet Easecto 80 mg chewable tablets for dogs >20-40 kg MiPet Easecto 120 mg chewable tablets for dogs >40-60 kg
Danish: MiPet Easecto 5 mg tyggetabletter til hunde på 1,3-2,5 kg MiPet Easecto 10 mg tyggetabletter til hunde på > 2,5-5 kg MiPet Easecto 20 mg tyggetabletter til hunde på > 5-10 kg MiPet Easecto 40 mg tyggetabletter til hunde på > 10-20 kg MiPet Easecto 80 mg tyggetabletter til hunde på > 20-40 kg MiPet Easecto 120 mg tyggetabletter til hunde på > 40-60 kg
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Danish: Særlige forholdsregler der skal træffes af personer, der administrerer lægemidlet til dyr: Vask hænder efter håndtering af produktet.
English: Veterinary medicinal product subject to prescription.
Danish: Veterinærlægemidlet er virksomt med øjeblikkelig virkning.
English: The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for at least 5 weeks.
Danish: Midlet dræber lopper og forebygger nye angreb i mindst 5 uger.
English: Wheat germ
Danish: Hvedekim
English: Chewable tablets
Danish: Tyggetabletter
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Efexor depot and associated names International Non-Proprietary Name (INN): venlafaxine
Danish: UDVALGET FOR HUMANMEDICINSKE LÆGEMIDLER (CHMP) UDTALELSE SOM FØLGE AF EN SAG INDBRAGT I HENHOLD TIL ARTIKEL 30 OM Efexor Depot og tilknyttede navne Internationalt fællesnavn (INN): venlafaxin
English: Efexor depot, 37.5 mg, 75 mg, 150 mg, hard prolonged-release capsules, is an antidepressant, indicated for the treatment of major depressive episodes, for the prevention of recurrence of major depressive episodes, for the treatment of social anxiety disorder, panic disorders with or without agoraphobia, and generalized anxiety disorder.
Danish: Efexor Depot, 37,5 mg, 75 mg, 150 mg, depotkapsler, hårde, er et antidepressivt lægemiddel til behandling af svære depressive episoder, til forebyggelse af recidiverende svære depressive episoder, til behandling af social angst, panikangst med eller uden agorafobi og generaliseret angst.
English: The basis for referral was that there were divergences in the Summaries of Product Characteristics (SPC) of Efexor depot approved across EU Member States, with respect to the treatment of major depressive episodes, the prevention of recurrence of major depressive episodes, the treatment of social anxiety disorder, panic disorders with or without agoraphobia, and generalized anxiety disorder.
Danish: Grundlaget for indbringelsen af sagen var, at der var afvigelser mellem de produktresuméer, der var godkendt for Efexor Depot i EU-medlemsstaterne, med hensyn til behandling af svære depressive episoder, til forebyggelse af recidiverende svære depressive episoder, behandling af social angst, panikangst med eller uden agorafobi og generaliseret angst.
English: On 3 May 2007, the European Commission presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, as amended, in order to harmonise the nationally authorised Summaries of Product Characteristics (SPC), Labelling and Package Leaflet of the medicinal product Efexor depot.
Danish: Den 3. maj 2007 indbragte Kommissionen en sag for EMEA i henhold til artikel 30 i direktiv 2001/83/EF, med senere ændringer, med henblik på harmonisering af de nationalt godkendte produktresuméer, etikettering og indlægsseddel for lægemidlet Efexor Depot.
English: The CHMP gave a positive opinion on 24 July 2008 with a subsequent revision on 25 September 2008 recommending the harmonisation of the SPC, Labelling and Package Leaflet for Efexor depot.
Danish: CHMP afgav en positive udtalelse den 24. juli 2008 efterfulgt af en revideret udtalelse den 25. september 2008 hvori udvalget anbefalede harmonisering af produktresumé, etikettering og indlægsseddel for Efexor Depot.
English: Neutropenia lasted 1 day on average with both medicines.
Danish: Neutropenien varede i gennemsnit 1 dag ved begge lægemidler.
English: Further information on Ziextenzo can be found on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/ziextenzo.
Danish: Yderligere information om Ziextenzo findes på agenturets websted under: https://www.ema.europa.eu/en/medicines/human/EPAR/ziextenzo.
English: This means that Ziextenzo is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Danish: Det betyder, at Ziextenzo i høj grad svarer til et andet biologisk lægemiddel ("referencelægemidlet"), der allerede er godkendt i EU.
English: What measures are being taken to ensure the safe and effective use of Ziextenzo?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Ziextenzo?
English: An overview of Ziextenzo and why it is authorised in the EU
Danish: En oversigt over Ziextenzo, og hvorfor det er godkendt i EU
English: Other information about Ziextenzo
Danish: Andre oplysninger om Ziextenzo
English: As for all medicines, data on the use of Ziextenzo are continuously monitored.
Danish: Som for alle lægemidler, er data vedrørende brug af Ziextenzo løbende overvåget.
English: Side effects reported with Ziextenzo are carefully evaluated and any necessary action taken to protect patients.
Danish: Bivirkninger rapporteret for Ziextenzo vurderes omhyggeligt, og der foretages nødvendige forholdsregler for at beskytte patienterne.
English: Ziextenzo is a ‘biosimilar medicine'.
Danish: Ziextenzo er et "biosimilært lægemiddel".
English: For more information about using Ziextenzo, see the package leaflet or contact your doctor or pharmacist.
Danish: For mere information om brug af Ziextenzo, se indlægssedlen eller kontakt lægen eller apotekspersonalet.
English: The most common side effect with Ziextenzo (which may affect more than 1 in 10 people) is pain in the bones.
Danish: Den hyppigste bivirkning ved Neulasta (som optræder hos mere end 1 ud af 10 patienter) er knoglesmerter.
English: Ziextenzo is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines).
Danish: Ziextenzo gives som en enkeltdosis på 6 mg, der injiceres under huden mindst 24 timer efter afslutningen af hver behandlingsserie med kemoterapi (behandling med kræftlægemidler).
English: Ziextenzo can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders.
Danish: Ziextenzo udleveres kun efter recept, og behandlingen bør iværksættes og overvåges af en læge med erfaring i behandling af kræft eller blodforstyrrelser.
English: What are the risks associated with Ziextenzo?
Danish: Hvilke risici er der forbundet med Ziextenzo?
English: The safety of Ziextenzo has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Neulasta.
Danish: Sikkerheden ved Ziextenzo er blevet vurderet, og på grundlag af alle de gennemførte studier anses bivirkningerne ved lægemidlet for at være sammenlignelige med bivirkningerne af referencelægemidlet Neulasta.
English: The reference medicine for Ziextenzo is Neulasta.
Danish: Referencelægemidlet for Ziextenzo er Neulasta.
English: The active substance in Ziextenzo, pegfilgrastim, is a form of filgrastim, which is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).
Danish: Det aktive stof i Ziextenzo, pegfilgrastim, er en form for filgrastim, der minder meget om det menneskelige protein granulocyt-kolonistimulerende faktor (G-CSF).
English: Because Ziextenzo is a biosimilar medicine, the studies on effectiveness and safety of pegfilgrastim carried out with Neulasta do not all need to be repeated for Ziextenzo.
Danish: Da Ziextenzo er et biosimilært lægemiddel, behøver de studier af pegfilgrastims virkning og sikkerhed, der er udført for Neulasta, ikke at blive gentaget for Ziextenzo.
English: Why is Ziextenzo authorised in the EU?
Danish: Hvorfor blev Ziextenzo godkendt i EU?
English: What is Ziextenzo and what is it used for?
Danish: Hvad er Ziextenzo, og hvad anvendes det til?
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Ziextenzo has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at det i overensstemmelse med EU's krav til biosimilære lægemidler er påvist, at Ziextenzo har en struktur, renhed og biologisk aktivitet, der svarer til Neulastas, og at det fordeles i kroppen på samme måde.
English: Therefore, the Agency's view was that, as for Neulasta, the benefit of Ziextenzo outweighs the identified risk and it can be authorised for use in the EU.
Danish: Agenturet var derfor af den opfattelse, at fordelene ved Ziextenzo opvejer de identificerede risici som for Neulasta, og at det kan godkendes til anvendelse i EU.
English: In addition, two studies involving 624 patients who had chemotherapy before or after surgery for breast cancer showed that Ziextenzo was as effective as Neulasta in reducing the duration of neutropenia.
Danish: Desuden viste to studier med 624 patienter, der var i behandling med kemoterapi før eller efter brystkræftoperation, at Ziextenzo var lige så effektivt som Neulasta til at reducere varigheden af neutropeni.
English: Ziextenzo is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia).
Danish: Ziextenzo er ikke beregnet til brug hos patienter med blodkræfttypen kronisk myeloid leukæmi eller myelodysplastisk syndrom (tilstand, hvor der produceres et stort antal blodlegemer, som kan udvikle sig til leukæmi).
English: It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever).
Danish: Ziextenzo gives specifikt for at reducere varigheden af neutropeni og forebygge såkaldt febril neutropeni, dvs. neutropeni ledsaget af feber.
English: It is available as a prefilled syringe containing a solution for injection under the skin.
Danish: Det fås som en fyldt pen med injektionsvæske til indsprøjtning under huden.
English: All these data were considered sufficient to conclude that Ziextenzo will behave in the same way as Neulasta in terms of effectiveness and safety in its authorised uses.
Danish: Disse oplysninger blev anset for tilstrækkelige til at konkludere, at Ziextenzo vil have de samme egenskaber som Neulasta, hvad angår sikkerhed og virkning ved de godkendte anvendelser.
English: In Ziextenzo, filgrastim has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Danish: I Ziextenzo er filgrastim blevet "pegyleret" (dvs. bundet til det kemiske stof polyethylenglykol).